Welcome to the Winter 2018/19 newsletter of the Centre for Health Economics and Medicines Evaluation (CHEME)

In this issue, we focus on recent achievements and events, which include:

- The STRAWB study, which received an ‘Outstanding Contribution to Midwifery Services’ award at the Maternity and Midwifery Festival 2018.
- The Trials Methodology Research Partnership, funded by the MRC-NIHR Methodology Research Programme to further develop research on trials-based economic evaluation.
- The presentation of the findings of a cost effectiveness study of point of care C-reactive protein testing to reduce antibiotic prescribing for respiratory tract infection at the Welsh Health Economics Group (WHEG) meeting.

Further information on research, teaching (including short courses) and NHS support activities is available on our website: cheme.bangor.ac.uk or contact our administrator Ann Lawton: cheme@bangor.ac.uk

Follow us on Twitter @CHEMEBangor

Professor Rhiannon Tudor Edwards & Professor Dyfrig Hughes
CHEME Co-directors
Exploring PTSD in Childbirth – the Stress and Wellbeing after Birth (STRAWB) trial

A recent study by Ayers and colleagues at City University, London found that between 3% and 4% of women report post-traumatic stress disorder (PTSD) in pregnancy and after birth. PTSD can affect the bond between mother and baby, and wider relationships between the mother and her partner. PTSD has significant implications for health services and clinical practice. PTSD may be preventable through targeted cognitive and behavioural interventions; however, the majority of evidence available was conducted with combat veterans, and more evidence is needed for different population groups.

In light of this evidence gap, Prof Rhiannon Tudor Edwards, Dr Joanna Charles and Lucy Bryning are working with Professor Pauline Slade and colleagues at the University of Liverpool and Liverpool Women’s Hospital to conduct a clinical and economic evaluation of the Stress and Wellbeing after Birth (STRAWB) trial. This is a randomised controlled trial, which screens post-partum women at risk of PTSD and provides self-help materials to those who screened positively. The self-help materials are a leaflet and videos. Women were recruited from four community midwifery teams located within Liverpool Women’s Hospitals Trust (Liverpool) and Lancashire Teaching Hospitals Trust (Preston). Economic findings are expected to be reported Spring 2019.

The STRAWB study received an award for ‘Outstanding Contribution to Midwifery Services’ at the Maternity and Midwifery Festival in Manchester, June 2018. The research was also shortlisted for the Royal College of Midwives annual awards in the category of Award for Excellence in Maternity Care, December 2018.

Economics of rare dementias

CHEME is partnering with University College London on a £5 million five year study funded by the ESRC looking at the care of people living with rare dementias. This will build on an ongoing study led by Nottingham funded by the NIHR, modelling the economics of interventions to support activities of daily living through exercise. CHEME are keen to collaborate with other health economic modellers working on economic evaluations of interventions for people with dementia.

Coaching and mentoring in health economics

Rhiannon Tudor Edwards is leading the HESG pilot mentoring scheme which will report in May 2019. She is an Institute of Leadership and Management qualified coach, recently gained her Wellbeing coaching qualification from the British School of Coaching, and is a member of the International Society for Qualified Coaches. The HESG scheme has gained interest from health economics organisations in Spain and the United States.

New appointment

Huw Lloyd-Williams has been appointed as a Research Officer in Health Technology Assessment working with Dyfrig Hughes. Huw will be working on a systematic review collating evidence on the economic evaluation of advanced therapy medicinal products (ATMPs). These are novel gene and cell therapy treatments which are very expensive. The review will identify studies that assess their cost effectiveness and the ways in which they are appraised and funded.
benefit-risk analysis

Drug development and regulatory decision-making require explicit evaluation of benefits and risks. In balancing the benefits and risks of medicines, judgements are required on the maximum acceptable risk of harm for an expected health benefit. The 21st Century Cures Act (section 3002) requires the FDA to develop guidance for integrating relevant patient experience data in benefit-risk assessments for new drugs and biologics. Research by Emily Holmes and Dyfrig Hughes demonstrated how this may be achieved by weighting clinical evidence by patients’ benefit-risk preferences. Using a case study of treatments for epilepsy, they found that accounting for patient preferences, in addition to clinical variables, could lead to different treatment choices or regulatory decisions (doi: 10.1002/cpt.1231).

Pharmacoeconomics

Registration is open for the upcoming short course in Pharmacoeconomics at Bangor University, 12th – 13th September, 2019

https://cheme.bangor.ac.uk/events/pharmacoeconomics-short-course-34917

Economic evaluations alongside trials

The MRC recently awarded funding to establish the Trials Methodology Research Partnership (TMRP) which brings together a number of networks, institutions and partners working in trials and trials methodology research. Led by Professor Paula Williamson of the University of Liverpool, the TMRP will offer an opportunity to build on the achievements of the MRC HTMR Network while exploring new collaborations and avenues to make continued progress in advancing trialsevaluation methodology, developing capacity and further reducing research waste.

The partner networks which will join the five Hubs within the MRC HTMR Network include the Global Health Network, Health Research Board Trials Methodology Research Network, Health Data Research UK, the UKCRC Registered CTU Network, the UK Trial Managers’ Network and 21 University centres. Dyfrig Hughes will lead on behalf of Bangor University and co-lead the Health Economics Working Group on research activities to extend the role of economic evaluations in stratified medicine, cost-effectiveness of digital tools in trials, and the use of expected value of sample information to inform adaptive trial design.

PRESENTATIONS...

Emily Holmes (CHEME) and David Gillespie (Cardiff University) delivered a workshop on “Medical adherence in clinical research” at The PRIME Centre Wales Annual Meeting in Pontypridd in November 2018.

PUBLICATIONS...

